Needham, MA (PRWEB) November 15, 2013
TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, has been nominated to serve as the 19th Surgeon General of the United States of America by President Barack Obama.
Dr. Murthy is currently an attending physician at Brigham and Women’s Hospital and an instructor at Harvard Medical School. In 2011, President Obama appointed Dr. Murthy to the Advisory Group on Prevention, Health Promotion, and Integrative and Public Health. His past research has focused on the participation of women and minorities in cancer clinical trials, and his writings and research have been published in Science, Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute, and The Washington Post.
Based on his lifelong commitment to patient wellness and his conviction that modern technology can be used to enhance collaboration among clinical researchers to accelerate drug discovery, Dr. Murthy co-founded TrialNetworks with CEO Eric Silberstein (his Harvard University classmate) and CTO Ezra Freedman.
“Dr. Murthy’s focus has always been on using his experience in medicine and science to find ways to help patients and improve healthcare on a broad scale,” said Silberstein. “His vision and insights led to the creation of TrialNetworks and our Clinical Trial Optimization System, which enables pharmaceutical companies to bring novel therapies to patients faster by running more efficient and higher-quality trials. It is exciting and an honor that Dr. Murthy will now have such a public platform to share and apply his expertise to benefit the health and wellness of individuals across our nation.”
TrialNetworks customers and clinical operations executives who know Dr. Murthy agree.
“Having worked with TrialNetworks for years, Dr. Murthy’s passion for improving the clinical research process is inspiring,” said Dr. Murray Abramson, MD, MPH, Vice President of Global Clinical Operations at Biogen Idec. “As a study sponsor and drug developer, I appreciate how TrialNetworks invests in its customer relationships and partners with us to create innovative technology that helps solve our clinical operational challenges. We wish him the best of luck in his new post.”
Upon confirmation by the U.S. Senate, Dr. Murthy will step down as Chairman of TrialNetworks.
Added Silberstein, “On behalf of TrialNetworks and our customers, I would like to thank Dr. Murthy for his years of guidance and friendship and congratulate him on this well-earned and honored nomination as America’s Doctor.”
TrialNetworks provides sponsors and CROs the industry's only Clinical Trial Optimization System. Using this modern and intuitive technology, customers such as Merck & Co. and Infinity Pharmaceuticals are able to transform the quality and efficiency of clinical operations at each stage of a trial from feasibility through closeout. TrialNetworks apps, including Checklist™, Training™, Document Library™, Visit Guide™, Action Items™ and Directory™, are available in a unified and secure cloud-based interface. Customers ranging from biotechs to Top-10 pharma companies have implemented the TrialNetworks platform for use in Phase I-IV trials by more than 25,000 site staff in 60 countries. To learn why sponsors and CROs rely on TrialNetworks to optimize clinical trial operations, request a guided online demo at http://www.trialnetworks.com.